The price of a drug should be based on its therapeutic benefits – not just what the market will bear

'Orphan drugs' with high price points are being tested as treatments for COVID-19. There's a better way to spur low-cost innovation for new drugs.

Nicole Hassoun, Professor of Philosophy, Binghamton University, State University of New York • conversation
Jan. 13, 2021 ~9 min

covid-19 rheumatoid-arthritis remdesivir pharmaceutical-industry drug-development innovation-and-invention process-of-innovation gilead

/

1